Abliva AB

Abliva discovers and develops medicines for the treatment of mitochondrial diseases. These rare and often very severe diseases occur when the cells energy provider, the mitochondria, do not function properly. The company has prioritized two projects. KL1333, a powerful regulator of the essential co-enzymes NAD+ and NADH, has entered late-stage development. NV354, an energy replacement therapy, has completed preclinical development. Abliva, based in Lund, Sweden, is listed on Nasdaq Stockholm, Sweden (ticker: ABLI)

Mitochondrial medicine,mitochondrial disorders,primary mitochondrial diseases,melas,and leigh

Abliva ab's HQ phone number is +46 46 275 62 21

Abliva ab's revenue is < 1m

Abliva ab has 11 - 50 employees.